Published in Curr HIV/AIDS Rep on March 01, 2013
Microbicide clinical trial adherence: insights for introduction. J Int AIDS Soc (2013) 1.47
Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). AIDS Res Hum Retroviruses (2015) 1.08
Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial. AIDS Behav (2014) 1.00
Evaluation of 3 approaches for assessing adherence to vaginal gel application in clinical trials. Sex Transm Dis (2013) 0.98
Disclosure of pharmacokinetic drug results to understand nonadherence. AIDS (2015) 0.96
Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa. PLoS One (2016) 0.91
An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV-based vaginal rings. J Int AIDS Soc (2014) 0.90
Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study. J Int AIDS Soc (2016) 0.87
Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions. AIDS Behav (2016) 0.85
Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings. J Int AIDS Soc (2016) 0.83
Summary measures of adherence using pill counts in two HIV prevention trials: the need for standardisation in reporting. AIDS Behav (2013) 0.83
Use of the dye stain assay and ultraviolet light test for assessing vaginal insertion of placebo-filled applicators before and after sex. Sex Transm Dis (2013) 0.83
Long acting systemic HIV pre-exposure prophylaxis: an examination of the field. Drug Deliv Transl Res (2017) 0.82
Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit? AIDS Behav (2016) 0.82
Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty. AIDS Behav (2016) 0.79
Evaluation of a multi-drug assay for monitoring adherence to a regimen for HIV pre-exposure prophylaxis in a clinical study (HIV Prevention Trials Network 073). Antimicrob Agents Chemother (2017) 0.75
Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet (2007) 7.22
Encouraging contraceptive uptake by motivating men to communicate about family planning: the Malawi Male Motivator project. Am J Public Health (2011) 2.06
Concurrent partnerships among adolescents in a Latino community: the Mission District of San Francisco, California. Sex Transm Dis (2007) 1.39
Epidemiological synergy of Trichomonas vaginalis and HIV in Zimbabwean and South African women. Sex Transm Dis (2010) 1.29
Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS (2013) 1.25
Novel strategies implemented to ensure high participant retention rates in a community based HIV prevention effectiveness trial in South Africa and Zimbabwe. Contemp Clin Trials (2009) 1.15
Qualitative assessment of venues for purposive sampling of hard-to-reach youth: an illustration in a Latino community. Sex Transm Dis (2004) 1.15
Asking mom: formative research for an HPV vaccine campaign targeting mothers of adolescent girls. J Health Commun (2011) 1.12
Vaginal practices and associations with barrier methods and gel use among Sub-Saharan African women enrolled in an HIV prevention trial. AIDS Behav (2010) 1.08
Patterns and predictors of adherence to diaphragm use in a phase III trial in sub-Saharan Africa: a trajectory analysis. J Acquir Immune Defic Syndr (2009) 1.05
The use of the diaphragm instead of condoms in a phase III diaphragm trial. AIDS Behav (2008) 1.00
Degrees of disclosure: a study of women's covert use of the diaphragm in an HIV prevention trial in sub-Saharan Africa. Soc Sci Med (2009) 0.98
Disclosure of pharmacokinetic drug results to understand nonadherence. AIDS (2015) 0.96
Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding". AIDS Behav (2015) 0.95
Feasibility, performance, and acceptability of the Wisebag™ for potential monitoring of daily gel applicator use in Durban, South Africa. AIDS Behav (2013) 0.91
Determinants of differential HIV incidence among women in three southern African locations. J Acquir Immune Defic Syndr (2011) 0.87
Influences on visit retention in clinical trials: insights from qualitative research during the VOICE trial in Johannesburg, South Africa. BMC Womens Health (2014) 0.87
Intimate partner violence and condom and diaphragm nonadherence among women in an HIV prevention trial in southern Africa. J Acquir Immune Defic Syndr (2013) 0.86
Age-Disparate Partnerships and Risk of HIV-1 Acquisition Among South African Women Participating in the VOICE Trial. J Acquir Immune Defic Syndr (2015) 0.83
A novel breath test to directly measure use of vaginal gel and condoms. AIDS Behav (2013) 0.80
Impact of learning HIV status on contraceptive use in the MIRA trial. J Fam Plann Reprod Health Care (2011) 0.80
A qualitative study of obstacles to diaphragm and condom use in an HIV prevention trial in sub-Saharan Africa. AIDS Educ Prev (2012) 0.79
A comparison of perinatal HIV prevention opportunities for Hispanic and non-Hispanic women in California. AIDS Educ Prev (2006) 0.78
Establishing a continuum of care between HIV prevention trials and public healthcare systems: the MIRA Standard of Care program. Clin Trials (2010) 0.78
Identifying factors that influence pregnancy intentions: evidence from South Africa and Malawi. Cult Health Sex (2014) 0.77
Unique challenges to preventing perinatal HIV transmission among Hispanic women in California: results of a needs assessment. AIDS Educ Prev (2005) 0.75